Suppr超能文献

癌症免疫疗法中的新机遇与挑战

Emerging Opportunities and Challenges in Cancer Immunotherapy.

作者信息

Whiteside Theresa L, Demaria Sandra, Rodriguez-Ruiz Maria E, Zarour Hassane M, Melero Ignacio

机构信息

Department of Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania.

Department of Radiation Oncology, University of Cornell, New York, New York.

出版信息

Clin Cancer Res. 2016 Apr 15;22(8):1845-55. doi: 10.1158/1078-0432.CCR-16-0049.

Abstract

Immunotherapy strategies against cancer are emerging as powerful weapons for treatment of this disease. The success of checkpoint inhibitors against metastatic melanoma and adoptive T-cell therapy with chimeric antigen receptor T cells against B-cell-derived leukemias and lymphomas are only two examples of developments that are changing the paradigms of clinical cancer management. These changes are a result of many years of intense research into complex and interrelated cellular and molecular mechanisms controling immune responses. Promising advances come from the discovery of cancer mutation-encoded neoantigens, improvements in vaccine development, progress in delivery of cellular therapies, and impressive achievements in biotechnology. As a result, radical transformation of cancer treatment is taking place in which conventional cancer treatments are being integrated with immunotherapeutic agents. Many clinical trials are in progress testing potential synergistic effects of treatments combining immunotherapy with other therapies. Much remains to be learned about the selection, delivery, and off-target effects of immunotherapy used alone or in combination. The existence of numerous escape mechanisms from the host immune system that human tumors have evolved still is a barrier to success. Efforts to understand the rules of immune cell dysfunction and of cancer-associated local and systemic immune suppression are providing new insights and fuel the enthusiasm for new therapeutic strategies. In the future, it might be possible to tailor immune therapy for each cancer patient. The use of new immune biomarkers and the ability to assess responses to therapy by noninvasive monitoring promise to improve early cancer diagnosis and prognosis. Personalized immunotherapy based on individual genetic, molecular, and immune profiling is a potentially achievable future goal. The current excitement for immunotherapy is justified in view of many existing opportunities for harnessing the immune system to treat cancer.

摘要

针对癌症的免疫治疗策略正成为治疗这种疾病的有力武器。检查点抑制剂治疗转移性黑色素瘤的成功,以及嵌合抗原受体T细胞过继性T细胞疗法治疗B细胞源性白血病和淋巴瘤的成功,只是正在改变临床癌症管理模式的众多进展中的两个例子。这些变化是多年来对控制免疫反应的复杂且相互关联的细胞和分子机制进行深入研究的结果。有前景的进展来自癌症突变编码新抗原的发现、疫苗开发的改进、细胞疗法递送方面的进步以及生物技术领域令人瞩目的成就。因此,癌症治疗正在发生根本性转变,传统癌症治疗正与免疫治疗药物相结合。许多临床试验正在进行,以测试免疫疗法与其他疗法联合使用的潜在协同效应。关于单独或联合使用免疫疗法的选择、递送和脱靶效应,仍有许多需要了解的地方。人类肿瘤进化出的众多逃避宿主免疫系统的机制仍然是成功的障碍。了解免疫细胞功能障碍以及癌症相关的局部和全身免疫抑制规则的努力正在提供新的见解,并激发了对新治疗策略的热情。未来,有可能为每位癌症患者量身定制免疫疗法。使用新的免疫生物标志物以及通过非侵入性监测评估治疗反应的能力有望改善癌症的早期诊断和预后。基于个体遗传、分子和免疫谱分析的个性化免疫疗法是一个潜在可实现的未来目标。鉴于利用免疫系统治疗癌症目前存在诸多机会,当前对免疫疗法的兴奋是合理的。

相似文献

1
Emerging Opportunities and Challenges in Cancer Immunotherapy.
Clin Cancer Res. 2016 Apr 15;22(8):1845-55. doi: 10.1158/1078-0432.CCR-16-0049.
2
Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Drug Resist Updat. 2017 May;32:1-15. doi: 10.1016/j.drup.2017.07.002. Epub 2017 Aug 19.
3
Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges.
Cancer Med. 2018 Sep;7(9):4517-4529. doi: 10.1002/cam4.1722. Epub 2018 Aug 7.
4
Advancing Immunotherapy in Metastatic Breast Cancer.
Curr Treat Options Oncol. 2017 Jun;18(6):35. doi: 10.1007/s11864-017-0478-9.
6
Immune Checkpoint Therapies in Prostate Cancer.
Cancer J. 2016 Mar-Apr;22(2):117-20. doi: 10.1097/PPO.0000000000000176.
7
Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Future Oncol. 2017 Aug;13(18):1649-1663. doi: 10.2217/fon-2017-0117. Epub 2017 Aug 4.
9
Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Clin Cancer Res. 2015 Dec 15;21(24):5543-51. doi: 10.1158/1078-0432.CCR-14-2009. Epub 2015 Jul 17.
10
Immune checkpoint inhibitors: The linchpins of modern immunotherapy.
Immunol Rev. 2019 Jul;290(1):6-23. doi: 10.1111/imr.12766.

引用本文的文献

1
Hydrogels as advanced drug delivery platforms for cancer immunotherapy: promising innovations and future outlook.
J Nanobiotechnology. 2025 Jul 28;23(1):545. doi: 10.1186/s12951-025-03613-6.
3
Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer.
Nat Rev Clin Oncol. 2025 Jun 9. doi: 10.1038/s41571-025-01029-7.
4
Assessment of compartment-specific CD103-positive cells for prognosis prediction of colorectal cancer.
Cancer Immunol Immunother. 2025 Jun 7;74(8):237. doi: 10.1007/s00262-025-04087-z.
6
Neoantigen-based immunotherapy: advancing precision medicine in cancer and glioblastoma treatment through discovery and innovation.
Explor Target Antitumor Ther. 2025 Apr 27;6:1002313. doi: 10.37349/etat.2025.1002313. eCollection 2025.
7
Current Landscape of Therapeutic Cancer Vaccines.
Methods Mol Biol. 2025;2926:1-14. doi: 10.1007/978-1-0716-4542-0_1.
8
The solid tumor microenvironment and related targeting strategies: a concise review.
Front Immunol. 2025 Mar 26;16:1563858. doi: 10.3389/fimmu.2025.1563858. eCollection 2025.
9
Battlegrounds of treatment resistance: decoding the tumor microenvironment.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Mar 25. doi: 10.1007/s00210-025-04055-5.
10

本文引用的文献

1
The role of regulatory T cells in cancer immunology.
Immunotargets Ther. 2015 Aug 5;4:159-71. doi: 10.2147/ITT.S55415. eCollection 2015.
2
Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.
Clin Cancer Res. 2016 Apr 15;22(8):1897-906. doi: 10.1158/1078-0432.CCR-15-1399.
3
Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines.
Clin Cancer Res. 2016 Apr 15;22(8):1885-96. doi: 10.1158/1078-0432.CCR-15-1509.
4
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy.
Clin Cancer Res. 2016 Apr 15;22(8):1875-84. doi: 10.1158/1078-0432.CCR-15-1433.
5
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.
Clin Cancer Res. 2016 Apr 15;22(8):1865-74. doi: 10.1158/1078-0432.CCR-15-1507.
6
Reversing T-cell Dysfunction and Exhaustion in Cancer.
Clin Cancer Res. 2016 Apr 15;22(8):1856-64. doi: 10.1158/1078-0432.CCR-15-1849.
8
Immune suppressive mechanisms in the tumor microenvironment.
Curr Opin Immunol. 2016 Apr;39:1-6. doi: 10.1016/j.coi.2015.10.009. Epub 2015 Nov 21.
9
Combination cancer immunotherapies tailored to the tumour microenvironment.
Nat Rev Clin Oncol. 2016 Mar;13(3):143-58. doi: 10.1038/nrclinonc.2015.209. Epub 2015 Nov 24.
10
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验